A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
This clinical trial is designed to investigate a new treatment, DS3790a, for people with blood cancers (hematological malignancies). It's an early-stage study, meaning it's one of the first times this medicine is being given to humans. The main aims are to understand how safe DS3790a is, what side effects it might cause, and to find the best dose. Researchers will also be looking at how well it works in shrinking tumours or making cancers disappear, both as a standalone treatment and potentially alongside other existing medicines like Epcoritamab or Rituximab. This trial will involve different groups of patients to explore these questions.
At a glance
What is this study about?
Imagine your body as a highly organised city, and sometimes, some cells start to grow out of control, causing what we call cancer. When this happens in your blood or bone marrow, it's known as a blood cancer or 'hematological malignancy'. Scientists are always looking for new and better ways to fight these diseases.
This particular study is testing a new medicine called DS3790a. It's a special type of drug designed to target specific markers on cancer cells, like a guided missile, to destroy them while potentially leaving healthy cells alone. This trial is called a 'first-in-human' study, which means it's one of the first times this medicine is being given to people. This is a crucial step in developing new treatments.
The main goals of this study are to make sure the medicine is safe, find out what side effects it might cause, and determine the best dose. Researchers will also carefully watch to see if the cancer shrinks or disappears completely, which is called a 'complete response'. Sometimes, this new medicine might be tested on its own, and other times, it might be tested with other treatments that are already used, like Epcoritamab or Rituximab, to see if they work even better together.
Key takeaways
- This study is testing a new medicine (DS3790a) for blood cancers.
- It's an early-stage study to check safety and find the best dose.
- Researchers will also look if the medicine helps the cancer shrink or disappear.
- You must be 18 or older to join, with no upper age limit.
- Participation involves regular hospital visits for treatment and check-ups.
- You can stop taking part at any time without affecting your normal care.
Who may be eligible?
To join this study, you must be an adult aged 18 or older. There is no upper age limit, meaning older adults can also take part. The study is open to both men and women.
Only people who have been diagnosed with a blood cancer are eligible. The healthcare team will check your specific type of blood cancer and your overall health to make sure this study is right for you and that taking part would be safe.
You would need to discuss your full medical history with the study doctors. They will have a detailed list of other health conditions, past treatments, and current medications that might prevent someone from joining. This is to ensure patient safety and to make sure the study results are as clear as possible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am 18 years old or older.
- I have been diagnosed with a blood cancer.
- I am able to attend regular hospital visits.
- I understand I will have various tests, like blood tests and scans.
- I am willing to discuss my full medical history with the study doctors.
What does participation involve?
If you decide to take part in this study, you would receive the study medicine, DS3790a, according to a schedule set by the researchers. This would involve regular visits to the hospital or clinic for your treatment and various tests.
During these visits, the medical team would closely monitor your health. This would include physical examinations, blood tests, and scans to see how your body is reacting to the medicine and if your cancer is responding. They would also ask about any side effects you might be experiencing.
The total length of time you would be in the study varies, as it depends on how your body responds to the treatment and the specific part of the study you are in. There will also be follow-up appointments after your treatment period to continue monitoring your health and any long-term effects.
Potential risks and benefits
Locations (2)
- —UnverifiedFrance
- —UnverifiedItaly
Common questions
What is a 'first-in-human' trial?
It means this is one of the first times this new medicine is being given to people, after extensive testing in the lab.
What kind of cancer is this study for?
This study is for different types of blood cancers, sometimes called hematological malignancies.
Will I get other medicines in this study?
Depending on the part of the study, you might receive DS3790a on its own, or sometimes with other existing medicines like Epcoritamab or Rituximab.
What does a 'complete response' mean?
A complete response means that the signs and symptoms of your cancer have disappeared after treatment.
Can I leave the study if I change my mind?
Yes, you can choose to stop participating in the study at any time, for any reason.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.